Morgan Stanley Maintains Pfizer (PFE) Equal-Weight Recommendation

Fintel reports that on April 10, 2023,
Morgan Stanley
maintained
coverage of Pfizer (NYSE:PFE) with
a Equal-Weight recommendation.

Analyst Price Forecast Suggests 24.43% Upside

As of April 6, 2023,
the average one-year price target for Pfizer is $51.94.
The forecasts range from a low of $40.40 to a high of $78.75.
The average price target represents an increase of 24.43% from its latest reported closing price of $41.74.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Pfizer
is $79,124MM, a decrease of 21.14%.

The projected annual non-GAAP EPS
is $5.02.

What are Other Shareholders Doing?

FXAIX – Fidelity 500 Index Fund
holds 60,859K shares
representing 1.08% ownership of the company.

In it’s prior filing, the firm reported owning 60,179K shares, representing
an increase
of 1.12%.

The firm

increased

its portfolio allocation in PFE by 7.74% over the last quarter.

Brighthouse Funds Trust II – MetLife Stock Index Portfolio
holds 1,130K shares
representing 0.02% ownership of the company.

In it’s prior filing, the firm reported owning 1,149K shares, representing
a decrease
of 1.73%.

The firm

increased

its portfolio allocation in PFE by 9.78% over the last quarter.

Wealth Enhancement Advisory Services
holds 205K shares
representing 0.00% ownership of the company.

In it’s prior filing, the firm reported owning 133K shares, representing
an increase
of 35.27%.

The firm

decreased

its portfolio allocation in PFE by 99.86% over the last quarter.

JOBIX – JOHCM Global Income Builder Institutional Shares
holds 6K shares
representing 0.00% ownership of the company.

In it’s prior filing, the firm reported owning 7K shares, representing
a decrease
of 25.98%.

The firm

increased

its portfolio allocation in PFE by 26.03% over the last quarter.

Tillman Hartley
holds 8K shares
representing 0.00% ownership of the company.

What is the Fund Sentiment?

There are 4629 funds or institutions reporting positions in Pfizer.

This is an increase
of
189
owner(s) or 4.26% in the last quarter.

Average portfolio weight of all funds dedicated to PFE is 0.59%,
a decrease
of 25.78%.

Total shares owned by institutions increased
in the last three months by 0.96% to 4,483,833K shares.

The put/call ratio of PFE is 1.03, indicating a

bearish
outlook.

Pfizer Background Information
(This description is provided by the company.)

Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives. It strives to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with its responsibility as one of the world’s premier innovative biopharmaceutical companies, it collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, it has worked to make a difference for all who rely on it. It routinely posts information that may be important to investors on its website at www.Pfizer.com.

See all Pfizer regulatory filings.

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.